COL-3, a Chemically Modified Tetracycline, Inhibits Lipopolysaccharide-Induced Microglia Activation and Cytokine Expression in the Brain

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Edan, Rawan Abdulhameed ^a   Luqmani, Yunus A ^a   Masocha, Willias ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

6 DIMETHYL DEOXY 4 DE(DIMETHYLAMINO)TETRACYCLINE; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; INCYCLINIDE; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; FEMALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; BRAIN; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MICROGLIA; TETRACYCLINES;

EID: 84874571929     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057827     Document Type: Article

References (59)

1. Rock RB, Gekker G, Hu S, Sheng WS, Cheeran M, et al. (2004) Role of microglia in central nervous system infections. Clin Microbiol Rev 17: 942-964, table of contents.
2. Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG, (2009) Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener 4: 47.
3. Amor S, Puentes F, Baker D, van der Valk P, (2010) Inflammation in neurodegenerative diseases. Immunology 129: 154-169.
4. Liu B, Hong JS, (2003) Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther 304: 1-7.
5. Wojtera M, Sikorska B, Sobow T, Liberski PP, (2005) Microglial cells in neurodegenerative disorders. Folia Neuropathol 43: 311-321.
6. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J, (1998) Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S A 95: 15769-15774.
7. Tikka TM, Vartiainen NE, Goldsteins G, Oja SS, Andersen PM, et al. (2002) Minocycline prevents neurotoxicity induced by cerebrospinal fluid from patients with motor neurone disease. Brain 125: 722-731.
8. Stirling DP, Koochesfahani KM, Steeves JD, Tetzlaff W, (2005) Minocycline as a neuroprotective agent. Neuroscientist 11: 308-322.
9. Guo G, Bhat NR, (2007) p38alpha MAP kinase mediates hypoxia-induced motor neuron cell death: a potential target of minocycline's neuroprotective action. Neurochem Res 32: 2160-2166.
10. Plane JM, Shen Y, Pleasure DE, Deng W, (2010) Prospects for minocycline neuroprotection. Arch Neurol 67: 1442-1448.
11. Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR, (1991) Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 2: 297-321.
12. Greenwald RA, Golub LM, Ramamurthy NS, Chowdhury M, Moak SA, et al. (1998) In vitro sensitivity of the three mammalian collagenases to tetracycline inhibition: relationship to bone and cartilage degradation. Bone 22: 33-38.
13. Fingleton B, (2003) CMT-3. CollaGenex. Curr Opin Investig Drugs 4: 1460-1467.
14. Dezube BJ, Krown SE, Lee JY, Bauer KS, Aboulafia DM, (2006) Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study. J Clin Oncol 24: 1389-1394.
15. Chu QS, Forouzesh B, Syed S, Mita M, Schwartz G, et al. (2007) A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas. Invest New Drugs 25: 359-367.
16. Chen J, Bookbinder M, Ryan ME, Golub LM, Ashley R, et al. (2001) Biodistribution of radiolabeled [(3)H] CMT-3 in rats. Curr Med Chem 8: 253-256.
17. Liu Y, Ramamurthy N, Marecek J, Lee HM, Chen JL, et al. (2001) The lipophilicity, pharmacokinetics, and cellular uptake of different chemically-modified tetracyclines (CMTs). Curr Med Chem 8: 243-252.
18. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, et al. (1999) Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 162: 3749-3752.
19. Lehnardt S, Massillon L, Follett P, Jensen FE, Ratan R, et al. (2003) Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci U S A 100: 8514-8519.
20. Kaneko YS, Mori K, Nakashima A, Sawada M, Nagatsu I, et al. (2005) Peripheral injection of lipopolysaccharide enhances expression of inflammatory cytokines in murine locus coeruleus: possible role of increased norepinephrine turnover. J Neurochem 94: 393-404.
21. Lund S, Christensen KV, Hedtjarn M, Mortensen AL, Hagberg H, et al. (2006) The dynamics of the LPS triggered inflammatory response of murine microglia under different culture and in vivo conditions. J Neuroimmunol 180: 71-87.
22. Henry CJ, Huang Y, Wynne A, Hanke M, Himler J, et al. (2008) Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J Neuroinflammation 5: 15.
23. Masocha W, (2009) Systemic lipopolysaccharide (LPS)-induced microglial activation results in different temporal reduction of CD200 and CD200 receptor gene expression in the brain. J Neuroimmunol 214: 78-82.
24. Kim SS, Kong PJ, Kim BS, Sheen DH, Nam SY, et al. (2004) Inhibitory action of minocycline on lipopolysaccharide-induced release of nitric oxide and prostaglandin E2 in BV2 microglial cells. Arch Pharm Res 27: 314-318.
25. Fan LW, Pang Y, Lin S, Rhodes PG, Cai Z, (2005) Minocycline attenuates lipopolysaccharide-induced white matter injury in the neonatal rat brain. Neuroscience 133: 159-168.
26. Horvath RJ, Nutile-McMenemy N, Alkaitis MS, Deleo JA, (2008) Differential migration, LPS-induced cytokine, chemokine, and NO expression in immortalized BV-2 and HAPI cell lines and primary microglial cultures. J Neurochem 107: 557-569.
27. Lokeshwar BL, Selzer MG, Zhu BQ, Block NL, Golub LM, (2002) Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model. Int J Cancer 98: 297-309.
28. Fan LW, Pang Y, Lin S, Tien LT, Ma T, et al. (2005) Minocycline reduces lipopolysaccharide-induced neurological dysfunction and brain injury in the neonatal rat. J Neurosci Res 82: 71-82.
29. Iravani MM, Leung CC, Sadeghian M, Haddon CO, Rose S, et al. (2005) The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation. Eur J Neurosci 22: 317-330.
30. Hart AD, Wyttenbach A, Perry VH, Teeling JL, (2012) Age related changes in microglial phenotype vary between CNS regions: grey versus white matter differences. Brain Behav Immun 26: 754-765.
31. Shao J, Liu T, Xie QR, Zhang T, Yu H, et al. (2012) Adjudin attenuates lipopolysaccharide (LPS)- and ischemia-induced microglial activation. J Neuroimmunol.
32. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
33. Tikka TM, Koistinaho JE, (2001) Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol 166: 7527-7533.
34. Maruyama M, Sudo T, Kasuya Y, Shiga T, Hu B, et al. (2000) Immunolocalization of p38 MAP kinase in mouse brain. Brain Res 887: 350-358.
35. Acharya MR, Venitz J, Figg WD, Sparreboom A, (2004) Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug Resist Updat 7: 195-208.
36. Roy SK, Kendrick D, Sadowitz BD, Gatto L, Snyder K, et al. (2011) Jack of all trades: pleiotropy and the application of chemically modified tetracycline-3 in sepsis and the acute respiratory distress syndrome (ARDS). Pharmacol Res 64: 580-589.
37. Roy A, Fung YK, Liu X, Pahan K, (2006) Up-regulation of microglial CD11b expression by nitric oxide. J Biol Chem 281: 14971-14980.
38. Roy A, Jana A, Yatish K, Freidt MB, Fung YK, et al. (2008) Reactive oxygen species up-regulate CD11b in microglia via nitric oxide: Implications for neurodegenerative diseases. Free Radic Biol Med 45: 686-699.
39. d'Avila JC, Lam TI, Bingham D, Shi J, Won SJ, et al. (2012) Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor. J Neuroinflammation 9: 31.
40. Block ML, Zecca L, Hong JS, (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8: 57-69.
41. Akiyama H, McGeer PL, (1990) Brain microglia constitutively express beta-2 integrins. J Neuroimmunol 30: 81-93.
42. Qin L, Wu X, Block ML, Liu Y, Breese GR, et al. (2007) Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 55: 453-462.
43. Sweet MJ, Hume DA, (1996) Endotoxin signal transduction in macrophages. J Leukoc Biol 60: 8-26.
44. An H, Yu Y, Zhang M, Xu H, Qi R, et al. (2002) Involvement of ERK, p38 and NF-kappaB signal transduction in regulation of TLR2, TLR4 and TLR9 gene expression induced by lipopolysaccharide in mouse dendritic cells. Immunology 106: 38-45.
45. Choi HB, Ryu JK, Kim SU, McLarnon JG, (2007) Modulation of the purinergic P2X7 receptor attenuates lipopolysaccharide-mediated microglial activation and neuronal damage in inflamed brain. J Neurosci 27: 4957-4968.
46. Tian D, Litvak V, Lev S, (2000) Cerebral ischemia and seizures induce tyrosine phosphorylation of PYK2 in neurons and microglial cells. J Neurosci 20: 6478-6487.
47. Svensson CI, Marsala M, Westerlund A, Calcutt NA, Campana WM, et al. (2003) Activation of p38 mitogen-activated protein kinase in spinal microglia is a critical link in inflammation-induced spinal pain processing. J Neurochem 86: 1534-1544.
48. Bu X, Huang P, Qi Z, Zhang N, Han S, et al. (2007) Cell type-specific activation of p38 MAPK in the brain regions of hypoxic preconditioned mice. Neurochem Int 51: 459-466.
49. Terayama R, Omura S, Fujisawa N, Yamaai T, Ichikawa H, et al. (2008) Activation of microglia and p38 mitogen-activated protein kinase in the dorsal column nucleus contributes to tactile allodynia following peripheral nerve injury. Neuroscience 153: 1245-1255.
50. Sandler C, Ekokoski E, Lindstedt KA, Vainio PJ, Finel M, et al. (2005) Chemically modified tetracycline (CMT)-3 inhibits histamine release and cytokine production in mast cells: possible involvement of protein kinase C. Inflamm Res. 54: 304-312.
51. Cazalis J, Tanabe S, Gagnon G, Sorsa T, Grenier D, (2009) Tetracyclines and chemically modified tetracycline-3 (CMT-3) modulate cytokine secretion by lipopolysaccharide-stimulated whole blood. Inflammation 32: 130-137.
52. Zhao F, Cai T, Liu M, Zheng G, Luo W, et al. (2009) Manganese induces dopaminergic neurodegeneration via microglial activation in a rat model of manganism. Toxicol Sci 107: 156-164.
53. Lai AY, Todd KG, (2006) Hypoxia-activated microglial mediators of neuronal survival are differentially regulated by tetracyclines. Glia 53: 809-816.
54. Lin S, Zhang Y, Dodel R, Farlow MR, Paul SM, et al. (2001) Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons. Neurosci Lett 315: 61-64.
55. Suk K, (2004) Minocycline suppresses hypoxic activation of rodent microglia in culture. Neurosci Lett 366: 167-171.
56. Yang LP, Zhu XA, Tso MO, (2007) Minocycline and sulforaphane inhibited lipopolysaccharide-mediated retinal microglial activation. Mol Vis 13: 1083-1093.
57. Skaletz-Rorowski A, Eschert H, Leng J, Stallmeyer B, Sindermann JR, et al. (2005) PKC delta-induced activation of MAPK pathway is required for bFGF-stimulated proliferation of coronary smooth muscle cells. Cardiovasc Res 67: 142-150.
58. Eklund KK, Sorsa T, (1999) Tetracycline derivative CMT-3 inhibits cytokine production, degranulation, and proliferation in cultured mouse and human mast cells. Ann N Y Acad Sci 878: 689-691.
59. Blum D, Chtarto A, Tenenbaum L, Brotchi J, Levivier M, (2004) Clinical potential of minocycline for neurodegenerative disorders. Neurobiol Dis 17: 359-366.